Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 1;76(3 Suppl):S94-100.
doi: 10.1016/j.ijrobp.2009.06.092.

Radiation-associated liver injury

Charlie C Pan  1 , Brian D Kavanagh, Laura A Dawson, X Allen Li, Shiva K Das, Moyed Miften, Randall K Ten Haken
Affiliations
Review

Radiation-associated liver injury

Charlie C Pan et al. Int J Radiat Oncol Biol Phys. .

Abstract

The liver is a critically important organ that has numerous functions including the production of bile, metabolism of ingested nutrients, elimination of many waste products, glycogen storage, and plasma protein synthesis. The liver is often incidentally irradiated during radiation therapy (RT) for tumors in the upper- abdomen, right lower lung, distal esophagus, or during whole abdomen or whole body RT. This article describes the endpoints, time-course, and dose-volume effect of radiation on the liver.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reference dose vs Effective Volume for 5% Isotoxicity curve for classic RILD after conformal radiation therapy, delivered in 1.5 Gy BID fractionation, for primary or metastatic tumors. Redrawn from [8]. The shaded areas around each curve represent the 80% confidence limits, which overlap above a reference dose of approximately 45 Gy.
Figure 2
Figure 2
Mean liver dose, corrected with LQ modeling for 2.0 Gy fractions, versus Lyman normal tissue complication probability (NTCP) of classic radiation-induced liver disease (RILD) for primary and metastatic liver cancer, redrawn from reference [24].
Figure 3
Figure 3
Characteristic normal liver (minus GTV) DVHs for low (A) or high (B) dose-per fraction. A. Mean normal liver DVHs from the University of Michigan for 204 patients who did or did not experience RILD. B. Mean normal liver DVHs from the University of Colorado SBRT Phase I trial with no radiation-induced liver disease (RILD) observed. See text for additional details.
Figure 3
Figure 3
Characteristic normal liver (minus GTV) DVHs for low (A) or high (B) dose-per fraction. A. Mean normal liver DVHs from the University of Michigan for 204 patients who did or did not experience RILD. B. Mean normal liver DVHs from the University of Colorado SBRT Phase I trial with no radiation-induced liver disease (RILD) observed. See text for additional details.
See this image and copyright information in PMC

References

    1. Yamasaki SA, Marn CS, Francis IR, et al. High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. AJR American Journal of Roentgenology. 1995;165:79–84. - PubMed
    1. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. International Journal of Radiation Oncology*Biology*Physics. 1995;31:1237–1248. - PubMed
    1. Xu Z-Y, Liang S-X, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2006;65:189–195. - PubMed
    1. Kim TH, Kim DY, Park J-W, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 2007;67:225–231. - PubMed
    1. Cheng JC-H, Wu J-K, Huang C-M, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. International Journal of Radiation Oncology*Biology*Physics. 2002;54:156–162. - PubMed